Morgan Stanley Onconova Therapeutics, Inc. Transaction History

Morgan Stanley

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Oct 17, 2024	SELL	$0.57 - $1.0 $341 - $600	-600 Reduced 3.18%	18,255 $10,000
Q2 2024 Aug 14, 2024	SELL	$0.57 - $1.0 $341 - $600	-600 Reduced 3.18%	18,255 $10,000
Q1 2024 Oct 17, 2024	BUY	$0.67 - $1.01 $402 - $606	600 Added 3.29%	18,855 $19,000
Q4 2023 Aug 16, 2024	BUY	$0.62 - $0.79 $372 - $474	600 Added 3.29%	18,855 $14,000
Q4 2023 Feb 13, 2024	SELL	$0.62 - $0.79 $778 - $991	-1,255 Reduced 6.24%	18,855 $14,000
Q2 2023 Aug 14, 2023	BUY	$0.67 - $1.42 $6,196 - $13,132	9,248 Added 85.14%	20,110 $23,000
Q3 2022 Nov 14, 2022	SELL	$0.95 - $1.45 $4,750 - $7,250	-5,000 Reduced 31.52%	10,862 $9,000
Q2 2022 Oct 27, 2022	SELL	$1.04 - $1.9 $1,139 - $2,082	-1,096 Reduced 6.46%	15,862 $21,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $1.9 $1,139 - $2,082	-1,096 Reduced 6.46%	15,862 $21,000
Q1 2022 Oct 27, 2022	BUY	$1.46 - $2.82 $1,600 - $3,090	1,096 Added 6.91%	16,958 $31,000
Q1 2022 May 13, 2022	BUY	$1.46 - $2.82 $953 - $1,841	653 Added 4.0%	16,958 $31,000
Q4 2021 Feb 14, 2022	SELL	$2.49 - $3.73 $74,704 - $111,907	-30,002 Reduced 64.79%	16,305 $41,000
Q3 2021 Nov 15, 2021	BUY	$3.81 - $6.76 $176,429 - $313,035	46,307 New	46,307 $177,000

1.67M

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.